Table 6 Incidence of breakthrough bleeding during treatment with EE/CMA or EE/DRSP
EE /CMA n (%) |
EE /DRSP n (%) | |
---|---|---|
Month 1 | 8 (9.0) | 15 (16.9) |
Month 3 | 8 (9.2) | 11 (12.4) |
Month 6 | 0 (0.0) | 2 (2.3) |
EE /CMA n (%) |
EE /DRSP n (%) | |
---|---|---|
Month 1 | 8 (9.0) | 15 (16.9) |
Month 3 | 8 (9.2) | 11 (12.4) |
Month 6 | 0 (0.0) | 2 (2.3) |